VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Interest Payable, Net
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Interest Payable, Net of $3.35 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2012-08-08
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in interest payable, net for the quarter ending 2012-03-31 was $3.35M, a 0.00% change year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in interest payable, net for the quarter ending 2011-12-31 was -$3.34M, a 199.61% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in interest payable, net for the quarter ending 2011-09-30 was $3.35M, a 2891.07% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in interest payable, net for the quarter ending 2011-06-30 was -$3.46M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in interest payable, net for fiscal 2011 was -$99.00K, a 103.27% decline from fiscal 2010.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in interest payable, net for fiscal 2010 was $3.03M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in interest payable, net for fiscal 2009 was -$1.42M, a 126.60% decline from fiscal 2008.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in interest payable, net for fiscal 2008 was $5.35M.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 3 month as first filed | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|---|
| 2012-03-31 | $3.35M 10-Q · filed 2012-05-10 | $13.00K derived: sum of 2 quarters · filed 2012-05-10 | $3.36M derived: sum of 3 quarters · filed 2012-05-10 | -$99.00K derived: sum of 4 quarters · filed 2012-08-08 | |
| 2011-12-31 | -$3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $13.00K derived: sum of 2 quarters · filed 2012-02-22 | -$3.45M derived: sum of 3 quarters · filed 2012-08-08 | -$99.00K 10-K · filed 2012-02-22 | |
| 2011-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$112.00K derived: sum of 2 quarters · filed 2012-08-08 | $3.24M 10-Q · filed 2011-11-03 | $6.59M derived: sum of 4 quarters · filed 2012-08-08 | |
| 2011-06-30 | -$3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$112.00K 10-Q · filed 2012-08-08 | $3.24M derived: sum of 3 quarters · filed 2012-08-08 | $3.35M derived: sum of 4 quarters · filed 2012-08-08 | |
| 2011-03-31 | $3.35M 10-Q · filed 2012-05-10 | $6.70M derived: sum of 2 quarters · filed 2012-05-10 | $6.81M derived: sum of 3 quarters · filed 2012-05-10 | $6.81M derived: sum of 4 quarters · filed 2012-05-10 | |
| 2010-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $3.46M derived: sum of 2 quarters · filed 2012-02-22 | $3.46M derived: sum of 3 quarters · filed 2012-02-22 | $3.03M 10-K · filed 2012-02-22 | |
| 2010-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $112.00K derived: sum of 2 quarters · filed 2011-11-03 | -$319.00K 10-Q · filed 2011-11-03 | $653.00K derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | -$431.00K 10-Q · filed 2011-08-09 | $541.00K derived: sum of 3 quarters · filed 2012-02-22 | -$1.17M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-03-31 | -$431.00K 10-Q · filed 2011-05-06 | $431.00K 10-Q · filed 2010-05-03 | $541.00K derived: sum of 2 quarters · filed 2012-02-22 | -$1.17M derived: sum of 3 quarters · filed 2012-02-22 | -$5.50M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | $972.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$738.00K derived: sum of 2 quarters · filed 2012-02-22 | -$5.07M derived: sum of 3 quarters · filed 2012-02-22 | -$1.42M 10-K · filed 2012-02-22 | |
| 2009-09-30 | -$1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$6.04M derived: sum of 2 quarters · filed 2010-10-28 | -$2.40M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | -$4.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-03 | -$685.00K 10-Q · filed 2010-08-03 | |||
| 2009-03-31 | $3.64M 10-Q · filed 2010-05-03 | ||||
| 2008-12-31 | $5.35M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |